{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:57:29Z","timestamp":1776355049648,"version":"3.51.2"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:p>This cohort study examines the association of bruton tyrosine kinase inhibitor therapy in B-cell malignant disease with increased risk of pericardial effusion and cardiovascular outcomes.<\/jats:p>","DOI":"10.1001\/jamaoncol.2025.6605","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:00:31Z","timestamp":1771516831000},"page":"419","source":"Crossref","is-referenced-by-count":0,"title":["Pericardial Effusion and Bruton Tyrosine Kinase Inhibitors in B-Cell Malignant Disease"],"prefix":"10.1001","volume":"12","author":[{"given":"Julia","family":"Zanco","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramzi","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang Nhat","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Medicine, University of Arizona, Tucson"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan M.","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn M.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hema","family":"Narayanasamy","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaji","family":"Tamarappoo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"5","key":"cld250032r1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology state-of-the-art review.","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"4","key":"cld250032r2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11886-023-01845-2","article-title":"Cardiovascular toxicities associated with tyrosine kinase inhibitors.","volume":"25","author":"Sayegh","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"cld250032r3","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1016\/j.chest.2023.07.344","article-title":"Ibrutinib-associated pericardial effusion with early tamponade in chronic lymphocytic leukemia: case report.","volume":"164","author":"Al Wahadneh","year":"2023","journal-title":"Chest"},{"key":"cld250032r4","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/2312182","article-title":"Pericarditis and cardiac tamponade in patients treated with first and second generation bruton tyrosine kinase inhibitors: an underappreciated risk.","volume":"2024","author":"Erblich","year":"2024","journal-title":"Case Rep Hematol"},{"issue":"1","key":"cld250032r5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77872","article-title":"Hemorrhagic pericardial effusion and cardiac tamponade in B-chronic lymphocytic leukemia treated with ibrutinib: a case report.","volume":"17","author":"Barton","year":"2025","journal-title":"Cureus"},{"issue":"4","key":"cld250032r6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.55729\/2000-9666.1509","article-title":"Beyond atrial fibrillation and heart failure: ibrutinib-induced pericardial effusion.","volume":"15","author":"Singh","year":"2025","journal-title":"J Community Hosp Intern Med Perspect"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2845276\/jamaoncology_zanco_2026_ld_250032_1775759231.64527.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:00:45Z","timestamp":1776351645000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2845276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.6605","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}